Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 185-191

  Baharivand, Nader ^a   Zarghami, Nosratollah ^b   Panahi, Farid ^c   Yazdan Dokht Ghafari, M ^c   Fard, Ali Mahdavi ^a   Mohajeri, Abbas ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Proliferative diabetic retinopathy; Vascular endothelial growth factor; Vitreous body

Indexed keywords

CREATININE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ALBUMIN TO CREATININE RATIO; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; MALE; MICROALBUMINURIA; PROTEIN BLOOD LEVEL; RENAL SYSTEM PARAMETERS; VITREOUS BODY;

EID: 84857000065     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S27423     Document Type: Article

References (39)

1. Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540-2553.
2. Singh R, Ramasamy K, Abraham C, Gupta V, Gupta A. Diabetic retinopathy: an update. Indian J Ophthalmol. 2008;56:178-188.
3. Perumalsamy N, Prasad NM, Sathya S, Ramasamy K. Software for reading and grading diabetic retinopathy: Aravind Diabetic Retinopathy Screening 3.0. Diabetes Care. 2007;30:2302-2306.
4. Akduman L, Olk RJ. The early treatment for diabetic retinopathy. In: Kerts C, editor. Clinical Trials in Ophthalmology - A Summary and Practice Guide. 3rd ed. Philadelphia, PA: Lippincott; 1998.
5. Aiello LM, Cavallerano JD, Aiello LP, Bursell SE. Diabetic retinopathy. In: Guyer DR, Yannuzzi LA, Chang S, editors. Retina Vitreous Macula. 6th ed. Philadelphia, PA: Saunders; 1999.
6. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556-563.
7. Rand LI, Prud'homme GJ, Ederer F, Canner PL. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci. 1985;26:983-991.
8. Fong DS, Segal PP, Myers F, Ferris FL, Hubbard LD, Davis MD. Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1997;115:873-877.
9. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol. 1990;108:958-964.
10. The DCCT Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46:271-286.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352: 837-853.
12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:786-806.
13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98: 823-833.
14. Garzia R, Borsting E, Nicholson S, Press L, Scheiman M, Solan H. Optometric Clinical Practice Guideline: Care of the Patient with Learning Related Vision Problems: Reference Guide for Clinicians. St Louis, MO: American Optometric Association; 2006.
15. Liesegang TJ, Skuta GL, Cantor LB. Retina and Vitreous. 25th ed. San Francisco, CA: LEO Publication; 2004.
16. Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002;133:693-698.
17. Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina. 2006;26:S71-S79.
18. Federman JL, Gouras P, Schubert HD. Systemic diseases. In: Podos SM, Yanoff M, editors. Retina and Vitreous - Textbook of Ophthalmology. 24th ed. New York, NY: McGraw Hill; 1994.
19. Pardianto G, et al. Understanding Diabetic Retinopathy in Mimbar Ilmiah Oftalmologi Indonesia. 2005.
20. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, editor. Retina. 2nd ed. Philadelphia, PA: Lippincott; 1994.
21. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
22. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995;270:13333-13340.
23. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med (Berl). 1995;73:333-346.
24. Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000;23:176.
25. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2002;86:311-315.
26. Hernandez C, Burgos R, Canton A, Garcia-Arumi J, Segura RM, Simo R. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2001;24:516-521.
27. Malik RA, Li C, Aziz W, et al. Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. J Cell Mol Med. 2005;9: 692-697.
28. Hernandez C, Lecube A, Segura RM, Sararols L, Simo R. Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2002;19:655-660.
29. Simo R, Lecube A, Segura RM, Garcia AJ, Hernandez C. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2002;134:376-382.
30. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139:476-481.
31. Sydorova M, Lee MS. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res. 2005;37:188-190.
32. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia. 2002;45:203-209.
33. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
34. Deng J, Wu DZ, Gao R. Elevated vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Yan Ke Xue Bao. 1999;15:17-21.
35. Ambati J, Chalam KV, Chawla DK, et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115:1161-1166.
36. Zhou H, Zhang H. A comparative study of vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Zhonghua Yan Ke Za Zhi. 1997;33:247-250. Chinese.
37. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
38. Burgos R, Simo R, Audi L, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 1997;40:1107-1109.
39. Shinoda K, Ishida S, Kawashima S, et al. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res. 2000;21:655-661.